Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia

Expert Opinion on Investigational Drugs

Volumn 21, Issue 6, 2012, Pages 871-878

  Thomas, Xavier ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Acute lymphoblastic leukemia; CMC 544; Inotuzumab ozogamicin; Monoclonal antibody; Targeted therapy

Indexed keywords

BUSULFAN; CALICHEAMICIN; CD22 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; DOFEQUIDAR; DOUBLE STRANDED DNA; DOXORUBICIN; FLUDARABINE; INOTUZUMAB OZOGAMICIN; LIVER ENZYME; MELPHALAN; PREDNISONE; RITUXIMAB; THIOTEPA; VALSPODAR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ASTHENIA; BONE MARROW CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL LINEAGE; CHROMOSOME ABERRATION; CYTOTOXICITY; DNA REPAIR; DOWN REGULATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TUMOR GROWTH; XENOGRAFT;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84861040649     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.679359     Document Type: Review

References (57)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2006;56:106-30
2. Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981;47:553-61 (Pubitemid 11051356)
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Hematol J 1997;1:53-66
4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78 (Pubitemid 43076714)
5. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-43
6. Hoelzer D. Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology 2011;243-9
7. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 2007;26:3704-13 (Pubitemid 46842705)
8. Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 2005;88:1-50 (Pubitemid 41439747)
9. Raponi S, Stefania de Propris M, Intoppa S, et al. Flow cytometry study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098-107
10. Gudowius S, Recker K, Laws HJ, et al. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Pediatr 2006;218:327-33 (Pubitemid 44862391)
11. Shan D, Press OW. Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 1995;154:4466-75
12. Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lumphocyte antigen receptor. Semin Immunol 1998;10:287-97 (Pubitemid 28375304)
13. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241-7 (Pubitemid 32695063)
14. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9 (Pubitemid 46606284)
15. Leonard JP, Coleman M, Ketas JC, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51 (Pubitemid 46224011)
16. Linden O, Hindorf C, Cavallin-Stahl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005;11:5215-22 (Pubitemid 41003709)
17. Dubowchik G, Walker M. Receptor-mediated and enzyme-dependent targeting of cytotoxic anti-cancer drugs. Pharmacol Ther 1999;83:67-123 (Pubitemid 29438597)
18. Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des 2000;6:1841-79
19. Zein N, Sinha AM, McGahren WJ, Ellestag GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201
20. Walker S, Landovitz R, Ding WD, et al. Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl Acad Sci USA 1992;89:4608-12
21. DiJoseph JF, Armellino DC, Bogaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 2004;103:1807-14 (Pubitemid 38268977)
22. DiJoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 2006;12:242-9 (Pubitemid 43166200)
23. Damle NK. Tumor-targeted chemotherapy using immunoconjugates of calicheamicin. Expert Opin Biol Ther 2004;4:1445-52 (Pubitemid 39222977)
24. Damle NK, Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol 2003;3:386-90 (Pubitemid 36908942)
25. DiJoseph JF, Dougher MM, Evans DY, et al. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted chemotherapy CVP or CHOP. Cancer Chemother Pharmacol 2011;67:741-9
26. DiJoseph JF, Dougher MM, Armellino DC, et al. Therapeutic potential of CD22-specific antibodytargeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007;21:2240-5 (Pubitemid 350011695)
27. Zwaan CM, Reinhardt D, Jurgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003;17:468-70 (Pubitemid 36277623)
28. De Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin- conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2011; [Epub ahead of print]
29. DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620-9 (Pubitemid 40053430)
30. Takeshita A, Shinjo K, Yamakage N, et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 2009;146:34-43
31. Takeshita A, Yamakage N, Shinjo K, et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immunoconjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 2009;23:1329-36
32. DiJoseph JF, Dougher MM, Kalyandrug L, Damle NK. Anti-tumor activity of CMC-544 in combination with rituximab [abstract #700]. Proc Am Assoc Cancer Res 2005;46:165
33. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556-63 (Pubitemid 350070832)
34. Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 2010;10:1251-8
35. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417-27
36. Fayad L, Patel H, Verhoef G, et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study [abstract #2711]. Blood 2006;108:766a
37. Johnson P, Fayad L, Coiffier B, et al. Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in recurrent/refractory follicular lymphoma or diffuse large B-cell lymphoma [abstract #407]. Haematologica 2009;94:165
38. Dang NH, Smith MR, Offner F, et al. Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma [abstract #584]. Blood 2009;114:242
39. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-93
40. Ogura M, Tobinai K, Hatake K, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci 2010;101:1840-5
41. Lobo E, Hansen R, Balthasar J. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-68 (Pubitemid 39506617)
42. Mager D, Jusko W. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001;28:507-32 (Pubitemid 34289541)
43. Brambell F, Hemmings W, Morris I. A theoretical model of gamma-globulin catabolism. Nature 1969;203:1352-4
44. Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012; [Epub ahead of print]
45. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet 2012; [Epub ahead of print]
46. Kebriaei P, Wilhelm K, Ravandi F, et al. Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic stem cell transplantation (HSCT) in remission in patients with advanced acute lymphoblastic leukemia (ALL). Blood 2011;118(suppl. 1)[abstract #3102]
47. Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001;15:163-205 (Pubitemid 32201872)
48. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-14 (Pubitemid 47299963)
49. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed acute lymphoblastic leukaemia. Cancer 1999;86:1216-30
50. Oriol A, Vives S, Hernandes-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukaemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589-96
51. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab. Blood 2007;109:4168-70 (Pubitemid 46743379)
52. Thomas D, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-80
53. Gokbuget N, Hoelzer D. Rituximab in the treatment of adult ALL. Ann Hematol 2006;85:117-19
54. Thomas D, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de-novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880-9
55. Thomas X, Olteanu N, Charrin C, et al. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol 2001;67:73-83
56. Robak T, Szmigielska-Kaplon A, Wrzesien-Kus A, et al. Acute lymphoblastic leukemia in elderly: the polish adult leukemia group experience. Ann Hematol 2004;83:225-31 (Pubitemid 38443507)
57. Pagano L, Mele L, Casorelli I, et al. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica 2000;85:1327-9 (Pubitemid 32063706)